Atul - The Life Science Segment Continues Its Stellar Performance
Atul (ATLP) reported revenue 7% above our expectation in 3QFY25. Revenue in the Life Science Chemicals segment increased 23% YoY
Atul - Rising like a Phoenix!
ATLP has burned for three long years (FY22-24) and it is a classic case ofvaluations perched higher despite a significant decline in earnings.
No more insights